CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 763 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04507763
NCT04507763N/ACompleted
CompareCT.gov

Clinical Outcomes of Early Versus Delayed Management of Iraqi Patients With Ankylosing Spondylitis (AS) With Etanercept

Pfizer·observational·Posted Aug 11, 2020·Updated Oct 28, 2021

In Brief

An observational study evaluating Etanercept for Ankylosing Spondylitis. Completed, enrolled 763 participants across 1 site.

Detailed Summary

This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesIraq
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 11, 2020
Enrollment StartAug 1, 2020
Primary CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.9 years ago

Interventions

Etanerceptdrug

Patients with ankylosing spondylitis as provided in real world practice